Dr. Reddy’s, Prestige BioPharma ink pact on cancer drug

DRL gets rights to commercialise proposed trastuzumab biosimilar in select LatAm, S-E Asia markets.

December 09, 2021 12:28 pm | Updated 12:32 pm IST - HYDERABAD:

Representational image only. File

Representational image only. File

Pharma major Dr. Reddy’s Laboratories has entered into a partnership with Prestige BioPharma under which it will get exclusive rights to supply and commercialise the Singapore firm’s proposed trastuzumab biosimilar in select Latin America and Southeast Asian countries.

Also read | UoH, Dr. Reddy's collaborate on potential drug for psoriasis

Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin. It can be prescribed for treatment of HER2 positive breast and metastatic gastric cancer, the two companies said in a release on a binding agreement they have signed.

CEO Lisa S. Park said the partnership with Dr. Reddy’s is for key Latin American and Southeast Asian markets. “Dr. Reddy’s is the ideal partner to commercialise our lead biosimilar in these territories. With the collaboration, we look forward to further strengthening value of our biosimilar programmes in global markets,” she said.

The license agreement grants Dr. Reddy’s exclusive rights to commercialise the proposed biosimilar in the select countries. Under their partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy’s will be responsible for local registrations, marketing and sales in the licensed territories.

Also read | Dr. Reddy's gets USFDA nod for generic anti-cancer drug

CEO – Branded Markets (India and Emerging Markets) of Dr. Reddy’s M. V. Ramana said the partnership is in line with the firm’s intent to create a portfolio of oncology products and expand biosimilar offerings in emerging markets. “The partnership will help combine Prestige BioPharma established expertise in the area of biosimilars with Dr. Reddy’s commercial strengths and growth ambition in these markets,” he said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.